Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; crospovidone; pregelatinised maize starch; indigo carmine aluminium lake - apo-levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. apo-levodopa/carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; magnesium stearate; pregelatinised maize starch; quinoline yellow aluminium lake; microcrystalline cellulose - levodopa/carbidopa gxp is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gxp frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; quinoline yellow aluminium lake; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate - levodopa/carbidopa gxp is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gxp frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; indigo carmine aluminium lake; crospovidone; magnesium stearate - levodopa/carbidopa genpar is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa genpar frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - levodopa, quantity: 250 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; magnesium stearate; indigo carmine aluminium lake; microcrystalline cellulose; pregelatinised maize starch - levodopa/carbidopa gxp is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa gxp frequently is helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with parkinson's disease and syndrome.

Canada - English - Health Canada

strides pharma canada inc - entacapone; carbidopa; levodopa - tablet - 200mg; 12.5mg; 50mg - entacapone 200mg; carbidopa 12.5mg; levodopa 50mg - catechol-o-methyltransferase (comt) inhibitors

Canada - English - Health Canada

strides pharma canada inc - entacapone; carbidopa; levodopa - tablet - 200mg; 37.5mg; 150mg - entacapone 200mg; carbidopa 37.5mg; levodopa 150mg - catechol-o-methyltransferase (comt) inhibitors

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25mg; levodopa 100mg - tablet - active: carbidopa monohydrate 27mg equivalent to carbidopa 25mg levodopa 100mg excipient: crospovidone magnesium stearate microcrystalline cellulose pregelatinised maize starch quinoline yellow - levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/ carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome. when therapeutic response to levodopa alone is irregular, and signs and symptoms of parkinson's disease are not evenly controlled throughout the day, substitution of levodopa/carbidopa usually is effective in reducing fluctuations in response. by reducing certain adverse reactions produced by levodopa alone, levodopa/carbidopa permits more patients to obtain adequate relief of the symptoms of parkinson's disease. levodopa/carbidopa is also indicated for patients with parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (vitamin b6).

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - carbidopa monohydrate 27mg equivalent to carbidopa 25mg; levodopa 250mg - tablet - active: carbidopa monohydrate 27mg equivalent to carbidopa 25mg levodopa 250mg excipient: crospovidone indigo carmine magnesium stearate microcrystalline cellulose pregelatinised maize starch - levodopa/carbidopa is indicated for the treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/ carbidopa frequently is helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome. when therapeutic response to levodopa alone is irregular, and signs and symptoms of parkinson's disease are not evenly controlled throughout the day, substitution of levodopa/carbidopa usually is effective in reducing fluctuations in response. by reducing certain adverse reactions produced by levodopa alone, levodopa/carbidopa permits more patients to obtain adequate relief of the symptoms of parkinson's disease. levodopa/carbidopa is also indicated for patients with parkinsonism who are taking vitamin preparations that contain pyridoxine hydrochloride (vitamin b6).

Israel - English - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - tablets controlled release - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.